Back to Search Start Over

Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia.

Authors :
Kashyap MK
Karathia H
Kumar D
Vera Alvarez R
Forero-Forero JV
Moreno E
Lujan JV
Amaya-Chanaga CI
Vidal NM
Yu Z
Ghia EM
Lengerke-Diaz PA
Achinko D
Choi MY
Rassenti LZ
Mariño-Ramírez L
Mount SM
Hannenhalli S
Kipps TJ
Castro JE
Source :
Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2024 Apr 26; Vol. 35 (2), pp. 102202. Date of Electronic Publication: 2024 Apr 26 (Print Publication: 2024).
Publication Year :
2024

Abstract

Splicing factor 3b subunit 1 (SF3B1) is the largest subunit and core component of the spliceosome. Inhibition of SF3B1 was associated with an increase in broad intron retention (IR) on most transcripts, suggesting that IR can be used as a marker of spliceosome inhibition in chronic lymphocytic leukemia (CLL) cells. Furthermore, we separately analyzed exonic and intronic mapped reads on annotated RNA-sequencing transcripts obtained from B cells ( n  = 98 CLL patients) and healthy volunteers ( n  = 9). We measured intron/exon ratio to use that as a surrogate for alternative RNA splicing (ARS) and found that 66% of CLL-B cell transcripts had significant IR elevation compared with normal B cells (NBCs) and that correlated with mRNA downregulation and low expression levels. Transcripts with the highest IR levels belonged to biological pathways associated with gene expression and RNA splicing. A >2-fold increase of active pSF3B1 was observed in CLL-B cells compared with NBCs. Additionally, when the CLL-B cells were treated with macrolides (pladienolide-B), a significant decrease in pSF3B1, but not total SF3B1 protein, was observed. These findings suggest that IR/ARS is increased in CLL, which is associated with SF3B1 phosphorylation and susceptibility to SF3B1 inhibitors. These data provide additional support to the relevance of ARS in carcinogenesis and evidence of pSF3B1 participation in this process.<br />Competing Interests: The authors declare no competing interests.<br /> (© 2024 The Authors.)

Details

Language :
English
ISSN :
2162-2531
Volume :
35
Issue :
2
Database :
MEDLINE
Journal :
Molecular therapy. Nucleic acids
Publication Type :
Academic Journal
Accession number :
38846999
Full Text :
https://doi.org/10.1016/j.omtn.2024.102202